Merck & Co., Inc. (NYSE:MRK) EVP Richard Deluca Sells 58,185 Shares of Company Stock

Merck & Co., Inc. (NYSE:MRK – Get Free Report) EVP Richard Deluca sold 58,185 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $148.01, for a total transaction of $8,611,961.85. Following the completion of the sale, the executive vice president directly owned 112,955 shares in the company, valued at $16,718,469.55. This represents a 34.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Merck & Co., Inc. Trading Down 2.2%

Shares of MRK stock traded down $3.27 on Monday, hitting $144.49. 8,320,922 shares of the company’s stock traded hands, compared to its average volume of 10,544,569. The company’s fifty day simple moving average is $146.16 and its 200 day simple moving average is $128.61. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.14 and a current ratio of 1.35. Merck & Co., Inc. has a one year low of $92.11 and a one year high of $156.92. The stock has a market capitalization of $356.20 billion, a price-to-earnings ratio of 148.96, a P/E/G ratio of 6.77 and a beta of 0.13.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.09 by $0.40. The company had revenue of $18.09 billion during the quarter, compared to analysts’ expectations of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. Merck & Co., Inc.’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the prior year, the business posted $2.58 EPS. Equities analysts forecast that Merck & Co., Inc. will post 2.82 EPS for the current year.

Institutional Investors Weigh In On Merck & Co., Inc.

Institutional investors have recently added to or reduced their stakes in the stock. Round Rock Advisors LLC grew its holdings in Merck & Co., Inc. by 0.7% during the 2nd quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock valued at $1,272,000 after buying an additional 66 shares in the last quarter. Cypress Wealth Services LLC grew its holdings in Merck & Co., Inc. by 0.5% during the 3rd quarter. Cypress Wealth Services LLC now owns 13,807 shares of the company’s stock valued at $1,960,000 after purchasing an additional 69 shares during the last quarter. Code Waechter LLC raised its holdings in shares of Merck & Co., Inc. by 3.4% in the third quarter. Code Waechter LLC now owns 2,179 shares of the company’s stock worth $317,000 after buying an additional 71 shares during the period. Quest 10 Wealth Builders Inc. increased its stake in Merck & Co., Inc. by 12.2% in the third quarter. Quest 10 Wealth Builders Inc. now owns 699 shares of the company’s stock worth $102,000 after purchasing an additional 76 shares during the period. Finally, Cascade Financial Partners LLC lifted its holdings in Merck & Co., Inc. by 0.5% during the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock valued at $1,895,000 after buying an additional 80 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

MRK has been the subject of a number of recent research reports. DZ Bank cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and set a $153.00 price target for the company. in a research report on Tuesday, November 3rd. Cantor Fitzgerald raised their price target on Merck & Co., Inc. from $145.00 to $155.00 and gave the stock a “neutral” rating in a research note on Monday, November 2nd. UBS Group raised their price objective on Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Guggenheim upped their target price on shares of Merck & Co., Inc. from $170.00 to $171.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Finally, Barclays boosted their price objective on Merck & Co., Inc. from $150.00 to $180.00 and gave the stock an “overweight” rating in a research note on Monday, October 26th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $155.74.

Read Our Latest Report on MRK

About Merck & Co., Inc.

(Get Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

Recommended Stories

Insider Buying and Selling by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.